Health: FDA News

Today is September 11, 2024. All times in Eastern Daylight Time.

InfuSystem and Sanara MedTech Inc. Announce Exclusive United States Distribution Agreement with ChemoMouthpiece, LLC

09/11/2024 - 06:30 AM

BUSINESS WIRE
Samenvatting: Delta-Fly Pharma Inc.: fase I/II Combo-studie van DFP-10917 met Venetoclax bij patiënten met AML begint met inschrijving van patiënten

09/10/2024 - 05:06 PM

BUSINESS WIRE
Riassunto: Delta-Fly Pharma Inc.: lo studio clinico di fase I/II di combinazione di DFP-10917 con Venetoclax in pazienti con LMA avvia la registrazione di pazienti

09/10/2024 - 05:02 PM

BUSINESS WIRE
Delta-Fly Pharma Inc. : début du recrutement pour l'étude combinée de phase I/II sur le DFP-10917 avec vénétoclax chez des patients atteints de LMA

09/10/2024 - 05:00 PM

BUSINESS WIRE
Resumen: Delta-Fly Pharma Inc: El estudio combinado de fase I/II de DFP-10917 con venetoclax en pacientes con LMA inicia la incorporación de pacientes

09/10/2024 - 04:56 PM

BUSINESS WIRE
Delta-Fly Pharma Inc.: Beginn der Patientenrekrutierung im Rahmen der Phase-I/II-Kombinationsstudie von DFP-10917 mit Venetoclax bei Patienten mit akuter myeloischer Leukämie (AML)

09/10/2024 - 04:53 PM

BUSINESS WIRE
FDA Grants 510(k) Clearance to Sonic Incytes' Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH

09/10/2024 - 02:02 PM

BUSINESS WIRE
FDA Grants Clearance for Immunis’ Phase II Sarcopenic Obesity Trial

09/10/2024 - 11:03 AM

BUSINESS WIRE
AscellaHealth Announces Expansion of Optime Care Specialty Pharmacy, Launches Additional Location at PA Headquarters to Support Operational Growth

09/10/2024 - 10:00 AM

BUSINESS WIRE
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

09/10/2024 - 09:32 AM

BUSINESS WIRE
Know Labs Study Published in IEEE Sensors Journal

09/10/2024 - 09:00 AM

BUSINESS WIRE
RION Announces Initiation of Phase 1b Clinical Study to Evaluate Purified Exosome Product™ (PEP™) for Knee Osteoarthritis

09/10/2024 - 09:00 AM

BUSINESS WIRE
Hinge Health Introduces Enso 3

09/10/2024 - 09:00 AM

BUSINESS WIRE
Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

09/10/2024 - 08:30 AM

BUSINESS WIRE
The Foundation for the National Institutes of Health Hosts Pioneering Research Meeting Celebrating Team Science and Its Role in Solving Major Biomedical Challenges

09/10/2024 - 08:17 AM

BUSINESS WIRE
New Breast Density Reporting Requirement Empowers Women with Vital Information; Susan G. Komen(R) Urges Access to Affordable Care

09/10/2024 - 08:15 AM

BUSINESS WIRE
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

09/10/2024 - 08:00 AM

BUSINESS WIRE
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

09/10/2024 - 07:30 AM

BUSINESS WIRE
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients

09/10/2024 - 07:00 AM

BUSINESS WIRE
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

09/10/2024 - 07:00 AM

BUSINESS WIRE
Incendia Therapeutics Enrolls First Patient in Phase 1c Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

09/10/2024 - 07:00 AM

BUSINESS WIRE
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

09/09/2024 - 04:05 PM

BUSINESS WIRE
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

09/09/2024 - 01:50 PM

BUSINESS WIRE
Battelle Awarded U.S. Department of Defense Contract to Develop an Improved Nerve Agent Countermeasure

09/09/2024 - 11:54 AM

BUSINESS WIRE
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024

09/09/2024 - 08:15 AM

BUSINESS WIRE

1 2 3 4 5 6 7 8

Next »

Search